l.	INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Application Number		10683929		
		Filing Date		2003-10-09		
		First Named Inventor John		in W. Rapp		
		Art Unit		2183		
		Examiner Name	David	J Huisman		
		Attorney Docket Numb	er	1934-013-03 (FE-00660)		

U.S.PATENTS					Remove						
Examiner Initial*	Cite No	F	Patent Number	Kind Code <sup>1</sup>				Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	6	112288		2000-08	1-29	Uliner				
	2	4	703475		1987-10	1987-10-27 Dretzka et al.					
3 6216191 2001-04-10 E		Britton et al.									
	4 5428754 1995-06-27		Baldwin								
If you wish to add additional U.S. Patent citation information please click the Add button. Add											
				U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove	
Examiner Cite No Publication Number Kind Code Date		Name of Pate of cited Docu	entee or Applicant ment	Rele	s,Columns,Lines where vant Passages or Relevant es Appear						
	1		20020087829		2002-07	-04	Snyder et al.				
If you wisi	h to ad	ld a	idditional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d butto	n. Add	
					FOREIG	GN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No		reign Document imber <sup>3</sup>	Country Code <sup>2</sup>			Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	

# Application Number 10683929

	Filing Date		2003-10-09		
INFORMATION DISCLOSURE	First Named Inventor	John	W. Rapp		
STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Art Unit		2183		
(Not for Submission under or or it issue	Examiner Name	David	d J Huisman		
	Attorney Docket Numb	er	1934-013-03 (FE-00660)		

	1	09457	788	EP EP		1999-09-29	TEXAS INSTRUMENTS INCORPORATED				
If you wish to add additional Foreign Patent Document citation information please click the Add button Add											
NON-PATENT LITERATURE DOCUMENTS Remove											
Examiner Cite Industrial Cite (Noc Industrial Cite Industrial											
	-										
If you wish to add additional non-patent literature document citation information please click the Add button Add											
	EXAMINER SIGNATURE										
Evenie	Evening Circuit and										

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10683929			
Filing Date		2003-10-09			
First Named Inventor	John	W. Rapp			
Art Unit		2183			
Examiner Name David		J Huisman			
Attorney Docket Number		1934-013-03 (FE-00660)			

#### CERTIFICATION STATEMENT

	Please see	37	CFR	1.97	and	1.98 to	make th	ne ap	propriate	selection(	S	j:
--	------------	----	-----	------	-----	---------	---------	-------	-----------	------------	---	----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e/t1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.5(r)(c).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

of the agradate.									
Signature	/Bryan A. Santarelli/	Date (YYYY-MM-DD)	2012-04-10						
Name/Print	Bryan A Santarelli	Registration Number	37560						

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2231-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, V.S. 2231-1450.

#### Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
  may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
  to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public fifthe record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by whiter a published application, an application open to public inscredience or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.